NatureWise Biotech & Medicals Overview
Valuation check: 4732.TWO's ROE is -31.12%, above the Healthcare sector average of -75.59%.
Get informed when a big investor buys or sells
+ Follow-31.12%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for 4732.TWO is -31.12%. That is above the Healthcare sector average of -75.59%. Investors often review this figure alongside NatureWise Biotech & Medicals's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, 4732.TWO currently prints -31.12% for ROE, while the sector average sits near -75.59%. That is roughly 58.8% above the sector mean. Large gaps often invite a closer look at NatureWise Biotech & Medicals's growth, margins, and balance sheet.
Return on Equity shows how effectively NatureWise Biotech & Medicals converts resources into returns. At -31.12%, 4732.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting 4732.TWO's ROE (-31.12%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack NatureWise Biotech & Medicals's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
